Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease

This publication has 21 references indexed in Scilit:

• Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
  BMJ, 1989
• The Clinical Significance of Serum C Reactive Protein Levels in Crohnʼs Disease
  Journal of Clinical Gastroenterology, 1988
• Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease
  Alimentary Pharmacology & Therapeutics, 1987
• Colonic release of 5‐amino salicylic acid from an oral preparation in active ulcerative colitis.
  British Journal of Clinical Pharmacology, 1983
• Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.
  BMJ, 1983
• Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease
  New England Journal of Medicine, 1980
• Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.
  Gut, 1980
• The Long-term Prophylactic Effect of Salazosulfapyridine (Salazopyrin^R) in Primarily Resected Patients with Crohn's Disease
  Scandinavian Journal of Gastroenterology, 1978
• AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
  The Lancet, 1977
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958